• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    uniQure N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    6/24/26 4:54:19 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QURE alert in real time by email
    false 0001590560 00-0000000 0001590560 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 23, 2026

     

    uniQure N.V.

    (Exact Name of Registrant as Specified in Charter)

     

    The Netherlands   001-36294   N/A
    (State or Other
    Jurisdiction of Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    Paasheuvelweg 25a,
    1105 BP
    Amsterdam, The Netherlands
      N/A
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: +31-20-240-6000

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:

    Ordinary Shares, par value €0.05 per share

      QURE   The Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01.Entry Into a Material Definitive Agreement.

     

    On June 23, 2026, uniQure N.V. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 4,945,055 of the Company’s ordinary shares (the “Firm Shares”), at a price to the public of $45.50 per ordinary share. Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option, exercisable for 30 days from the date of the Underwriting Agreement (the “Option”), to purchase up to an additional 741,758 of the Company’s ordinary shares (the “Optional Shares” and together with the Firm Shares, the “Shares”) at the public offering price less the underwriting discounts and commissions. On June 24, 2026, the Underwriters exercised the Option in full.

     

    The Company estimates that the net proceeds from the Offering will be approximately $242.7 million after deducting underwriting discounts and commissions and estimated offering expenses.

     

    The Shares will be issued pursuant to a prospectus supplement dated June 23, 2026, and an accompanying base prospectus that form a part of the registration statement on Form S-3ASR that the Company filed with the Securities and Exchange Commission on January 7, 2025 (File No. 333-284168), which was automatically effective upon its filing. The closing of the Offering is expected to take place on or about June 25, 2026, subject to the satisfaction of customary closing conditions.

     

    The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions.

     

    A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1 and is incorporated herein by reference. The foregoing description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibits.

     

    The legal opinion of NautaDutilh as to the legality of the Shares is being filed as Exhibit 5.1 to this Current Report on Form 8-K.

     

    Item 8.01Other Events

     

    On June 23, 2026, the Company issued a press release entitled “uniQure Announces Pricing of Upsized $225 Million Public Offering.” The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d)            Exhibits.

     

    Exhibit No.   Description
    1.1   Underwriting Agreement, dated as of June 23, 2026, by and between the Company and Leerink Partners LLC, as representative for the several underwriters named therein.
         
    5.1   Opinion of NautaDutilh.
         
    23.1   Consent of NautaDutilh (included in Exhibit 5.1).
         
    99.1   Press Release of uniQure N.V. dated June 23, 2026.
         
    104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      UNIQURE N.V.
       
    Date: June 24, 2026 By: /s/ Jeannette Potts
        JEANNETTE POTTS
        Chief Legal and Compliance Officer

     

     

     

    Get the next $QURE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QURE

    DatePrice TargetRatingAnalyst
    6/18/2026$65.00Equal Weight → Overweight
    Barclays
    6/17/2026$61.00Neutral → Overweight
    Cantor Fitzgerald
    6/17/2026Neutral → Overweight
    Cantor Fitzgerald
    3/11/2026$35.00Neutral → Outperform
    Mizuho
    3/9/2026$60.00Equal Weight → Overweight
    Wells Fargo
    3/9/2026$35.00Sector Perform → Outperform
    RBC Capital Mkts
    3/3/2026$15.00Overweight → Equal Weight
    Wells Fargo
    3/3/2026$12.00Outperform → Neutral
    Mizuho
    More analyst ratings

    $QURE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

    LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were

    6/25/26 4:10:00 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Pricing of Upsized $225 Million Public Offering

    LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 4,945,055 ordinary shares at a public offering price of $45.50 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $225 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-d

    6/23/26 9:13:55 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces $150 Million Proposed Public Offering

    LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its ordinary shares on the same terms and conditions. The offering is subject to market and othe

    6/22/26 4:01:00 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Managing Director Kapusta Matthew C exercised 67,237 units of Ordinary Shares at a strike of $20.24 and sold $9,371,612 worth of Ordinary Shares (206,100 units at $45.47) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 521,795 units (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    6/22/26 8:31:27 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Balachandran Madhavan exercised 11,685 units of Ordinary Shares at a strike of $24.97 and sold $526,485 worth of Ordinary Shares (11,685 units at $45.06) as part of a pre-agreed trading plan (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    6/22/26 8:05:31 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaye Jack exercised 5,295 units of Ordinary Shares at a strike of $31.71 and sold $225,408 worth of Ordinary Shares (5,295 units at $42.57) as part of a pre-agreed trading plan (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    6/22/26 7:54:03 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    SEC Filings

    View All

    SEC Form 144 filed by uniQure N.V.

    144 - uniQure N.V. (0001590560) (Subject)

    6/25/26 4:00:26 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - uniQure N.V. (0001590560) (Filer)

    6/24/26 4:54:19 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by uniQure N.V.

    424B5 - uniQure N.V. (0001590560) (Filer)

    6/24/26 4:52:56 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    uniQure upgraded by Barclays with a new price target

    Barclays upgraded uniQure from Equal Weight to Overweight and set a new price target of $65.00

    6/18/26 8:13:29 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded uniQure from Neutral to Overweight and set a new price target of $61.00

    6/17/26 11:50:18 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure upgraded by Cantor Fitzgerald

    Cantor Fitzgerald upgraded uniQure from Neutral to Overweight

    6/17/26 11:47:28 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Leadership Updates

    Live Leadership Updates

    View All

    uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

    ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

    6/11/25 8:00:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

    LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab's appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He

    6/26/23 7:11:42 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    11/14/24 12:01:42 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    11/13/24 4:05:14 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    10/25/24 9:48:27 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Financials

    Live finance-specific insights

    View All

    uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

    ~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~ ~ Progressing AMT-130 toward expected UK regulatory submission; MAA on track for third quarter of 2026 following successful pre-submission meeting with UK MHRA ~ ~ Enrollment in AMT-260 temporal lobe epilepsy program on track; clinical update from first cohort in Phase I/IIa study to be presented at the Epilepsy Foundation Pipeline Conference ~ ~ Presented updated data from AMT-191 Phase I/IIa in Fabry disease study showed sustained increases in α-Gal A Enzyme Activity and stable Lyso-Gb3 levels; subsequently all 11 dosed patients have discontinued enzyme replacement

    5/5/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure to Announce First Quarter 2026 Financial Results

    ~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, April 28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2026 financial results before market open on Tuesday, May 5, 2026. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure's website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and

    4/28/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces 2025 Financial Results and Provides Recent Company Updates

    ~ Held Type A meeting with FDA to discuss AMT-130 for Huntington's disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of 2026 ~ ~ Completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026 ~ ~ Presented updated Phase I/II data from AMT-191 in Fabry disease showing durable, dose-dependent increases in α-Gal A enzyme activity ~ ~ Cash, cash equivalents and current investment securities of approximately $622.5 million as of December 31, 2025 expected to fund operations into the second

    3/2/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care